Lixte Biotechnology

Lixte Biotechnology

Lixte Biotechnology was founded in 2005 by Dr. John S. Kovach, a physician-scientist with a long career at the National Cancer Institute before establishing the company. Its work centers on targeting the protein phosphatase PP2A, a tumor suppressor enzyme that cancer cells frequently disable. Lixte's approach seeks to reactivate PP2A, restoring a natural braking mechanism on uncontrolled cell growth. The company maintains its headquarters in Pasadena, California, and operates as a public entity. Lixte's pipeline is built on its lead compound, LB-100, a PP2A inhibitor that paradoxically makes cancer cells more vulnerable to other treatments when used in combination. The strategy is to pair LB-100 with standard chemotherapy or immunotherapy to overcome drug resistance. The company has advanced LB-100 into early-stage clinical trials for various solid tumors, including small-cell lung cancer and colorectal cancer. Its research collaborations span academic medical centers in the United States and Europe. Lixte holds a portfolio of patents protecting its mechanism-of-action approach. As a micro-cap biotech, Lixte operates with a lean infrastructure, relying on grants, clinical partnerships, and public market financing to fund its trials. The team is small and research-focused. The company has previously attracted non-dilutive funding from the National Institutes of Health (NIH) to support its clinical development programs. The company's common stock is listed on the Nasdaq Capital Market. Lixte's structural differentiator is its mechanism-first model: rather than chasing a specific gene mutation, it targets a master enzymatic switch found across many cancers. This gives the pipeline potential breadth against tumors that share drug-resistance pathways, but it also requires proving a complex biological hypothesis in human trials — a high-risk, high-reward posture typical of deep-science public biotechs.